The above observations suggest that TβRII is a major target in the attenuation of TGF-β signaling activity during hepatocarcinogenesis and TGF-β treatment produced an apparent tumor suppressive activity in all HCC cell lines that are sensitive to TGF-β. The gene discussed is TGFBR2; the disease is hepatocellular carcinoma.